Adjustment of Eculizumab Dosage Pattern in Patients with Atypical Hemolytic Uremic Syndrome with Suboptimal Response to Standard Treatment Pattern

Table 2

Eculizumab doses administered to patient 2 and analytical data after the corresponding eculizumab administration.

Phase	Week: dose number	ECU; IV (mg)	Platelets; (number/μL)	LDH; (IU/L)	Hemoglobin; (mg/dL)	Haptoglobin; (mg/dL)	Schistocytes (% in blood)	Serum creatinine; (mg/dL)
Initiation	1: 1	900	110,000	317	8	<3	3	12.1
	2: 2	900	116,000	229	9.9	—	<1	13.3
	3: 3	900	62,000	186	10.1	—	—	11.2
	4: 4	900	68,000	—	8.9	—	—	—
Maintenance	5: 5	1,200	65,000	299	7.9	<3	0	8.3
	7: 6	1,200	84,000	—	8.3	—	0	4.7
	9: 7	1,200	131,000	150	9.7	<3	0	5.7
	12:	1,200	189,000	143	10.6	—	<0,01	3.7
	14: 9	1,200	208,000	—	13.5	13	—	4.4
	16: 10	1,200	113,000	91	14.6	—	—	4.5
	18: 11	1,200	142,000	117	14.4	36	<0,1	4.1

The modified eculizumab dosage pattern is highlighted in bold: the 6th dose of eculizumab was administered 12 days after the 5th (3 days earlier than scheduled according to the center’s protocol).
administration of the 8th dose of eculizumab was delayed 6 days due to bacteriemia.
ECU: eculizumab; LDH: lactate dehydrogenase.